Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in RLAY.

← Back to Free Index

RLAY

Analysis as of: 2026-02-13

Relay Therapeutics, Inc.

Clinical-stage biotechnology company developing small-molecule medicines for oncology and genetic disease, led by zovegalisib (RLY-2608).

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Breakthrough designation sets up a pivotal-dose inflection

A Breakthrough-designated PI3Kα program with a near-term dose-level dataset can non-linearly re-rate the asset if benefit-risk holds at the Phase 3 dose. The main risk remains a binary pivotal outcome against a rapidly improving competitive standard.

Analysis

Thesis

BTD for zovegalisib and a near-term Phase 3–dose dataset can shift RLAY from “single-asset option value” to a launchable PI3Kα franchise by 2031; upside compounds if it owns the PI3KCA testing→therapy workflow and extends durability via a proprietary combo strategy.

Last Economy Alignment

Cheaper compute accelerates small-molecule iteration (Dynamo), but value is still proof-gated by Phase 3 and FDA; durable upside comes from IP + real-world data/workflow rails.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

6.1x (from 5 most recent analyses)

Reasoning

RLAY’s 5-year outcome is dominated by a step-function de-risking and launch-visibility rerate: a credible Phase 3-dose profile (near-term) plus eventual registrational success can rapidly move the market from “trial risk” to “commercial ramp.” The best operator move is building distribution rails (testing→therapy→outcomes) so the product becomes the default path in biomarker-positive patients, defending share even as competitors and formularies optimize.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

RLAY is primarily a clinical-validation trade: one registrational program drives most 2031 value. Secondary risks are the competitive bar moving (better-tolerated combos), diagnostic/payer friction limiting uptake, and dilution if trials + launch spend outlast the current runway.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

2026-02-03: FDA granted Breakthrough Therapy designation for zovegalisib + fulvestrant in PIK3CA-mutant HR+/HER2- advanced/metastatic breast cancer after CDK4/6 therapy.
Next high-signal catalyst remains the first public Phase 3-dose (400mg BID fed) combination dataset at ESMO TAT on 2026-03-16.

Thesis update

Core thesis unchanged (pivotal proof is the gate), but formal BTD confirmation and the near-dated Phase 3-dose disclosure tighten the de-risking path assumptions.

Forecast update

Regulatory momentum and clearer near-term de-risking improved the probability-weighted path to a commercial valuation within the horizon.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.28

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$14.84

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research